- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents
Patent holdings for IPC class A61P 7/04
Total number of patents in this class: 1824
10-year publication summary
|
59
|
99
|
128
|
118
|
163
|
143
|
184
|
139
|
140
|
110
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bioverativ Therapeutics Inc. | 212 |
51 |
| The Children's Hospital of Philadelphia | 867 |
29 |
| Chugai Seiyaku Kabushiki Kaisha | 1422 |
29 |
| Genzyme Corporation | 1383 |
28 |
| Cellphire, Inc. | 109 |
26 |
| Takeda Pharmaceutical Company Limited | 2699 |
25 |
| Novo Nordisk A/S | 2284 |
20 |
| Laboratoire Francais du Fractionnement et des Biotechnologies | 298 |
17 |
| CSL Behring Lengnau AG | 125 |
17 |
| Baxter International Inc. | 1885 |
16 |
| The University of North Carolina at Chapel Hill | 2116 |
16 |
| Baxter Healthcare S.A. | 1393 |
15 |
| Novo Nordisk Health Care AG | 313 |
15 |
| Pfizer Inc. | 3413 |
13 |
| Baxalta Incorporated | 297 |
12 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3327 |
12 |
| The Trustees of the University of Pennsylvania | 4432 |
11 |
| Osaka University | 3261 |
11 |
| The General Hospital Corporation | 4879 |
10 |
| CSL Behring GmbH | 348 |
10 |
| Other owners | 1441 |